Network Insights Methodology Get Access

Novartis

ORG Health Care / Pharmaceuticals Momentum 9.9ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. CRITICALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$61B revenue (2025), Basel pharma giant Novartis advanced broad immunology portfolio at EULAR 2026 while betting on actinium for male contraception via Series B capital deployment. Recent signals show expansion into high-growth myopia market and cross-sector infrastructure partnerships.

Novartis invested in male contraception startup Series B funding round ($92.5M); active in immunology portfolio expansion and myopia market development; partnership activity with industrials sector (Nucor, US Forged Rings).
0.05
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
9.9
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
25
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Novartis is getting less coverage than expected — the market may be ignoring a developing story (primary driver: Attention Cascade).
Connected Entities
Pfizer Merck China European Union PlocamiumAI United States Anthropic AstraZeneca CEO North Carolina Eli Lilly Texas DOD Senator Germany
Watch This Entity
PSI Intelligence
30-Day Trend
2026-05-11 2026-06-10 25 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.000
Spectral Shift
536.271
Sentiment-Momentum Divergence
0.000
Source Concentration
0.786
Signal
Novartis is getting less coverage than expected — the market may be ignoring a developing story (primary driver: Attention Cascade).
Driver
Ranked #6 of 6 in Health Care — in line with sector peers. PSI stable vs yesterday (-1.00). Confidence: 63% (entity has limited history, score is shrunk toward sector prior).
Action
Baseline conditions. Continue standard monitoring cadence.
Peer Comparison
6 of 6
Sector Rank
+0.00
Peer Z-Score
0%
Sector Percentile
Network Analysis
25 Degree Centrality
Ego Network (top connections)
Pfizer (weight 85.0)Merck (weight 84.0)China (weight 7.0)European Union (weight 7.0)PlocamiumAI (weight 7.0)United States (weight 7.0)Anthropic (weight 5.0)AstraZeneca (weight 4.0) PfizerMerckChinaEuropean UnionPlocamiumAIUnited StatesAnthropicAstraZeneca Novartis (degree 25) Novartis
Centrality History
2026-05-11 2026-06-10 25 0 Degree Mentions
EntityWeight StatusFirst Seen
Pfizer 85 NEW
Merck 84 NEW
China 7 NEW
European Union 7 NEW
PlocamiumAI 7 NEW
United States 7 NEW
Anthropic 5 NEW
AstraZeneca 4 NEW
CEO 4 NEW
North Carolina 4 NEW
Eli Lilly 3 NEW
Texas 3 NEW
DOD 3 NEW
Senator 2 NEW
Germany 2 NEW
United Kingdom 2 NEW
Boeing 2 NEW
Intel 2 NEW
Ohio 2 NEW
SEC 2 NEW
TSMC 2 NEW
FDA 2 NEW
Airbus 2 NEW
Asia 2 NEW
Barclays 2 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-06-10 ← Intelligence Network